I
Intarcia Therapeutics
Develops innovative therapies aimed at Diabetes
About Intarcia Therapeutics
Intarcia Therapeutics is a pioneering company focused on redesigning the treatment of chronic diseases through innovative therapies that integrate medicine with technology. Operating in the biopharmaceutical sector, Intarcia serves patients suffering from chronic conditions, aiming to improve their quality of life with advanced drug delivery systems. The company's core product is the Medici Drug Delivery System, an investigational technology designed to provide consistent and long-term delivery of medication. Intarcia's business model revolves around the development and commercialization of these cutting-edge therapies, generating revenue through partnerships, licensing agreements, and direct sales. By placing patients at the center of their mission, Intarcia is committed to transforming therapeutic categories and setting new standards in chronic disease management.
Source: Dealroom company dataNews
Open roles
Intarcia Therapeutics in the Boston ecosystem
The Intarcia Therapeutics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series B and later10 investors entered at this stage
Alta Partners
InterWest Partners
Venrock
NEA
Notable Capital
Marker LLC
RA Capital Management
Farallon Capital Management
Baillie Gifford
Bill & Melinda Gates Foundation
Source: Dealroom Talent Intelligence.
Patents
21 active patent families included in this estimate.
A patent family groups patent filings for the same invention. Source: Dealroom · PatSnap.
See Intarcia Therapeutics on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.

